Automated Manufacturing of CD20.19 Bi-Specific Chimeric Antigen Receptor T (CAR-T) Cells at an Academic Center for a Phase I Clinical Trial in Relapsed, Refractory NHL

被引：0
|
作者：
Zhu, Fenlu [1 ]
Shah, Nirav N. [2 ]
Schneider, Dina [3 ]
Xu, Huiqing [1 ]
Chaney, Katherine [4 ]
Luib, Lawrence [5 ]
Keever-Taylor, Carolyn [6 ]
Dropulic, Boro [3 ]
Orentas, Rimas [7 ]
Hari, Parameswaran [2 ]
Johnson, Bryon D. [1 ]
机构：
[1] Med Coll Wisconsin, Milwaukee, WI 53226 USA
[2] Med Coll Wisconsin, BMT & Cellular Therapy Program, Hematol Oncol, Med, Milwaukee, WI 53226 USA
[3] Lentigen Technol Inc, Gaithersburg, MD USA
[4] Med Coll Wisconsin, Med, Milwaukee, WI 53226 USA
[5] Froedtert Hosp, Milwaukee, WI USA
[6] Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA
[7] Seattle Childrens Hosp, Seattle, WA USA
来源：
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2019年 / 25卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
77
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Point-of-Care Manufacturing of CD20.19 Bi-Specific Chimeric Antigen Receptor T (CAR-T) Cells in a Standard Academic Cell Processing Flexibility for a Phase I Clinical Trial in Relapsed, Refractory NHL
    Zhu, Fenlu
    Shah, Nirav N.
    Schneider, Dina
    Xu, Huiqing
    Chaney, Katherine
    Luib, Lawrence
    Keever-Taylor, Carolyn A.
    Dropulic, Boro
    Orentas, Rimas
    Hari, Parameswaran
    Johnson, Bryon
    BLOOD, 2018, 132
  • [2] Developing a Novel Anti-CD19/CD20 Bi-Specific Chimeric Antigen Receptor T (CAR-T) Cell Therapy for Relapsed/Refractory (r/r) B-Cell NHL
    Zhou, Lili
    Huang, Jiaqi
    Zhu, Shigui
    Yao, Xin
    Ye, Shiguang
    Zhu, Judy
    Zheng, Chengxiao
    Chen, Shiyi
    Li, Yanfeng
    Lan, Liping
    Chen, Shicheng
    Guo, Lin
    Zhang, Qingsong
    Zheng, Jiangqin
    Wang, Rirfei
    Hong, Yi
    Ren, Jiaqiang
    Zhang, Li
    Zhang, Wenjun
    Tang, Xiaochen
    Wang, Junbang
    Liu, Jie
    Humphries, Michael
    Li, Ping
    Yao, Yihong
    Liang, Aibin
    BLOOD, 2020, 136
  • [3] A Phase I clinical trial of chimeric antigen receptor-modified T cells in patients with relapsed and refractory lymphoma
    Chen, Xinfeng
    Li, Xin
    Liu, Yanfen
    Zhang, Zhen
    Zhang, Xudong
    Huang, Jianmin
    Li, Hong
    Li, Feng
    Zhang, Lei
    Li, Ling
    Wu, Xiaolong
    Ma, Wang
    Sun, Zhenchang
    Yu, Hui
    Zhou, Zhiyuan
    Feng, Xiaoyan
    Cui, Kang
    Li, Zhaoming
    Zhang, Hongling
    Zeng, Ying
    Wan, Xiaochun
    Chen, Youhai H.
    Zhang, Mingzhi
    Zhang, Yi
    IMMUNOTHERAPY, 2020, 12 (10) : 681 - 696
  • [4] Humanized CD19-targeted chimeric antigen receptor T (CAR-T) cells for relapsed/refractory pediatric acute lymphoblastic leukemia
    Wang, Shiyuan
    Wang, Xue
    Ye, Chunying
    Cheng, Hai
    Shi, Ming
    Chen, Wei
    Qi, Kunming
    Wang, Gang
    Wu, Qingyun
    Zeng, Lingyu
    Li, Zhenyu
    Jing, Guangjun
    Zheng, Junnian
    Xu, Kailin
    Cao, Jiang
    AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (05) : E162 - E165
  • [5] A Phase I Clinical Trial of Fully Human Anti-CD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies
    Cooper, Brenda W.
    Gallogly, Molly Megan
    Metheny, Leland
    Klisovic, Rebecca B.
    Boughan, Kirsten Marie
    Koc, Jane Reese
    Wu, Darong
    Deng, Changchun
    Van Besien, Koen
    Tupta, Rose
    Schneider, Dina
    Ciarrone, Lisa
    de Lima, Marcos
    Caimi, Paolo F.
    Tomlinson, Benjamin K.
    BLOOD, 2023, 142
  • [6] LOCALLY MANUFACTURED AUTOLOGOUS CD19 CHIMERIC ANTIGEN RECEPTOR-T (CAR-T) CELLS FOR PHASE II PROSPECTIVE CLINICAL TRIAL FOR RELAPSED/REFRACTORY B-ACUTE LYMPHOBLASTIC LEUKAEMIA IN MALAYSIA
    Lim, T. S.
    Nyunt, W.
    Then, K.
    Cheong, S.
    Then, K.
    Ooi, G.
    Govindasamy, V.
    Idris, M. Mohd
    Azura, S.
    Abdullah, N.
    Zakaria, M. Muhd
    Chang, A. H.
    Ithnin, A.
    Wahid, S. S. Abdul
    CYTOTHERAPY, 2023, 25 (06) : S225 - S226
  • [7] APRIL CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma: A Phase I Clinical Trial
    Li, Wenxiao
    Hu, Yongxian
    Zhang, Mingming
    Lai, Xinyi
    Zhao, Mengyu
    Fu, Shan
    Hong, Ruimin
    Chang, Alex H.
    Huang, He
    BLOOD, 2024, 144 : 7229 - 7229
  • [8] Sustained remissions with CD19-specific chimeric antigen receptor (CAR)-modified T cells in children with relapsed/refractory ALL
    Maude, Shannon L.
    Teachey, David T.
    Rheingold, Susan R.
    Shaw, Pamela A.
    Aplenc, Richard
    Barrett, David Maxwell
    Barker, Christine S.
    Callahan, Colleen
    Frey, Noelle V.
    Nazimuddin, Farzana
    Lacey, Simon F.
    Zheng, Zhaohui
    Levine, Bruce
    Melenhorst, Jan Joseph
    Motley, Laura
    Porter, David L.
    June, Carl H.
    Grupp, Stephan A.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [9] Naturally Selected CD7-Targeted Chimeric Antigen Receptor (CAR)-T Cell Therapy for Refractory/Relapsed Acute Myeloid Leukemia: Phase I Clinical Trial
    Xian Zhang
    Junfang Yang
    Jingjing Li
    Liyuan Qiu
    Liu Hongxing, Sr.
    Min Xiong
    Jianqiang Li
    Peihua Lu
    BLOOD, 2023, 142
  • [10] Safety and Efficacy of CD19 CAR-T Cells for Refractory Systemic Sclerosis: A Phase I Clinical Trial
    Feng, Jingjing
    Hu, Yongxian
    Zhang, Mingming
    Cao, Heng
    Ke, Yini
    Xu, Huijun
    Cui, Jiazhen
    Zhang, Yanlei
    Chang, Alex Hongsheng
    Lin, Jin
    Wei, Guoqing
    Huang, He
    BLOOD, 2022, 140 : 10335 - 10336
12345